JP Morgan Reinstates Underweight on Emergent BioSolutions
JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.
A big investment bank's expert says Emergent BioSolutions stock looks less attractive right now than other choices. This is a signal to watch the company more carefully—it hints the expert sees challenges ahead, even if nothing terrible happened today.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.